PDI loses another pharma contract
Contract sales provider PDI said Sanofi-Aventis would end its $20 million sales agreement with the firm, effective Dec. 1. It was set to expire Dec. 31, PDI said.
The end of the firm's Sanofi-Aventis deal comes a month after GlaxoSmithKline decided not to renew a $65 million to $70 million contract with PDI for 2007.
In April, AstraZeneca also ended a $65 million-$70 million agreement with PDI, affecting approximately 800 field reps.
PDI “has been significantly impacted” as the world's top pharma companies re-evaluate their commercial models, CEO Michael Marquad said in a statement.